Tasquinimod: A novel angiogenesis inhibitor-development in prostate cancer

Saby George, Roberto Pili

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Castration resistant prostate cancer (CRPC) treatment has been revolutionized over the past few years by the approval of novel therapies including cabazitaxel, sipuleucel-T, abiraterone and enzalutamide. Though androgen deprivation and chemotherapy remain the main therapeutic approaches for this disease, a series of targeted agents is also in development for the treatment of CRPC. Tasquinimod is a quinolone-3-carboxamide with antiangiogenic and antitumor activity in preclinical models of prostate cancer. A recent Phase II trial with this agent has demonstrated a significant clinical activity in asymptomatic or minimally symptomatic, chemotherapy-naïve, CRPC patients. A confirmatory Phase III trial of tasquinimod in prostate cancer is underway. Because of its antiangiogenic and immunomodulatory properties tasquinimod represents a novel targeted therapy with a unique mechanism of action.

Original languageEnglish (US)
Pages (from-to)65-68
Number of pages4
JournalCurrent Oncology Reports
Volume15
Issue number2
DOIs
StatePublished - Apr 2013
Externally publishedYes

Fingerprint

Angiogenesis Inhibitors
Prostatic Neoplasms
Castration
Therapeutics
Drug Therapy
Quinolones
Androgens
tasquinimod

Keywords

  • Adenocarcinoma of prostate
  • Angiogenesis inhibitor
  • Castration resistant prostate cancer (CRPC)
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Tasquinimod : A novel angiogenesis inhibitor-development in prostate cancer. / George, Saby; Pili, Roberto.

In: Current Oncology Reports, Vol. 15, No. 2, 04.2013, p. 65-68.

Research output: Contribution to journalArticle

@article{816262e8b5df4d439882b965e2d87e19,
title = "Tasquinimod: A novel angiogenesis inhibitor-development in prostate cancer",
abstract = "Castration resistant prostate cancer (CRPC) treatment has been revolutionized over the past few years by the approval of novel therapies including cabazitaxel, sipuleucel-T, abiraterone and enzalutamide. Though androgen deprivation and chemotherapy remain the main therapeutic approaches for this disease, a series of targeted agents is also in development for the treatment of CRPC. Tasquinimod is a quinolone-3-carboxamide with antiangiogenic and antitumor activity in preclinical models of prostate cancer. A recent Phase II trial with this agent has demonstrated a significant clinical activity in asymptomatic or minimally symptomatic, chemotherapy-na{\"i}ve, CRPC patients. A confirmatory Phase III trial of tasquinimod in prostate cancer is underway. Because of its antiangiogenic and immunomodulatory properties tasquinimod represents a novel targeted therapy with a unique mechanism of action.",
keywords = "Adenocarcinoma of prostate, Angiogenesis inhibitor, Castration resistant prostate cancer (CRPC), Targeted therapy",
author = "Saby George and Roberto Pili",
year = "2013",
month = "4",
doi = "10.1007/s11912-013-0295-7",
language = "English (US)",
volume = "15",
pages = "65--68",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "2",

}

TY - JOUR

T1 - Tasquinimod

T2 - A novel angiogenesis inhibitor-development in prostate cancer

AU - George, Saby

AU - Pili, Roberto

PY - 2013/4

Y1 - 2013/4

N2 - Castration resistant prostate cancer (CRPC) treatment has been revolutionized over the past few years by the approval of novel therapies including cabazitaxel, sipuleucel-T, abiraterone and enzalutamide. Though androgen deprivation and chemotherapy remain the main therapeutic approaches for this disease, a series of targeted agents is also in development for the treatment of CRPC. Tasquinimod is a quinolone-3-carboxamide with antiangiogenic and antitumor activity in preclinical models of prostate cancer. A recent Phase II trial with this agent has demonstrated a significant clinical activity in asymptomatic or minimally symptomatic, chemotherapy-naïve, CRPC patients. A confirmatory Phase III trial of tasquinimod in prostate cancer is underway. Because of its antiangiogenic and immunomodulatory properties tasquinimod represents a novel targeted therapy with a unique mechanism of action.

AB - Castration resistant prostate cancer (CRPC) treatment has been revolutionized over the past few years by the approval of novel therapies including cabazitaxel, sipuleucel-T, abiraterone and enzalutamide. Though androgen deprivation and chemotherapy remain the main therapeutic approaches for this disease, a series of targeted agents is also in development for the treatment of CRPC. Tasquinimod is a quinolone-3-carboxamide with antiangiogenic and antitumor activity in preclinical models of prostate cancer. A recent Phase II trial with this agent has demonstrated a significant clinical activity in asymptomatic or minimally symptomatic, chemotherapy-naïve, CRPC patients. A confirmatory Phase III trial of tasquinimod in prostate cancer is underway. Because of its antiangiogenic and immunomodulatory properties tasquinimod represents a novel targeted therapy with a unique mechanism of action.

KW - Adenocarcinoma of prostate

KW - Angiogenesis inhibitor

KW - Castration resistant prostate cancer (CRPC)

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84879600997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879600997&partnerID=8YFLogxK

U2 - 10.1007/s11912-013-0295-7

DO - 10.1007/s11912-013-0295-7

M3 - Article

C2 - 23334511

AN - SCOPUS:84879600997

VL - 15

SP - 65

EP - 68

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 2

ER -